-
1
-
-
0345601083
-
Met, metastasis, motility and more
-
DOI 10.1038/nrm1261
-
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640)
-
(2003)
Nature Reviews Molecular Cell Biology
, vol.4
, Issue.12
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
Vande, W.G.F.4
-
2
-
-
0030039519
-
Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network
-
Jeffers M, Rong S, Vande Woude GF (1996) Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-MET signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125. (Pubitemid 26061683)
-
(1996)
Molecular and Cellular Biology
, vol.16
, Issue.3
, pp. 1115-1125
-
-
Jeffers, M.1
Rong, S.2
Vande, W.G.F.3
-
3
-
-
33746504571
-
Invasive growth: A MET-driven genetic programme for cancer and stem cells
-
DOI 10.1038/nrc1912, PII NRC1912
-
Boccaccio C, Comoglio PM (2006) Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6(8):637-645. (Pubitemid 44140861)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.8
, pp. 637-645
-
-
Boccaccio, C.1
Comoglio, P.M.2
-
4
-
-
0041737535
-
Molecular mechanisms of glioma invasiveness: The role of proteases
-
Rao JS (2003) Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer 3(7):489-501.
-
(2003)
Nat Rev Cancer
, vol.3
, Issue.7
, pp. 489-501
-
-
Rao, J.S.1
-
5
-
-
0034020459
-
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
-
DOI 10.1038/75596
-
Holland EC, et al. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25:55-57. (Pubitemid 30257036)
-
(2000)
Nature Genetics
, vol.25
, Issue.1
, pp. 55-57
-
-
Holland, E.C.1
Celestino, J.2
Dai, C.3
Schaefer, L.4
Sawaya, R.E.5
Fuller, G.N.6
-
6
-
-
0035256772
-
Gliomagenesis: Genetic alterations and mouse models
-
Holland EC (2001) Gliomagenesis: Genetic alterations and mouse models. Nat Rev Genet 2:120-129.
-
(2001)
Nat Rev Genet
, vol.2
, pp. 120-129
-
-
Holland, E.C.1
-
7
-
-
33847066415
-
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition
-
Tsuda M, et al. (2007) TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67:919-929.
-
(2007)
Cancer Res
, vol.67
, pp. 919-929
-
-
Tsuda, M.1
-
8
-
-
0032564341
-
The mutationally activated Met receptor mediates motility and metastasis
-
DOI 10.1073/pnas.95.24.14417
-
Jeffers M, et al. (1998) The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 95:14417-14422. (Pubitemid 28549382)
-
(1998)
Proceedings of the National Academy of Sciences of the United States of America
, vol.95
, Issue.24
, pp. 14417-14422
-
-
Jeffers, M.1
Fiscella, M.2
Webb, C.P.3
Anver, M.4
Koochekpour, S.5
Vande, W.G.F.6
-
9
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
Turke AB, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77-88.
-
(2010)
Cancer Cell
, vol.17
, pp. 77-88
-
-
Turke, A.B.1
-
10
-
-
0030690583
-
Met and hepatocyte growth factor/scatter factor expression in human gliomas
-
Koochekpour S, et al. (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57:5391-5398. (Pubitemid 27516379)
-
(1997)
Cancer Research
, vol.57
, Issue.23
, pp. 5391-5398
-
-
Koochekpour, S.1
Jeffers, M.2
Rulong, S.3
Taylor, G.4
Klineberg, E.5
Hudson, E.A.6
Resau, J.H.7
Vande, W.G.F.8
-
11
-
-
54549108740
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
-
Network CGAR, Cancer Genome Atlas Research Network
-
Network CGAR, Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
-
(2008)
Nature
, vol.455
, pp. 1061-1068
-
-
-
12
-
-
73649123907
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
-
Cancer Genome Atlas Research Network
-
Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110.
-
(2010)
Cancer Cell
, vol.17
, Issue.1
, pp. 98-110
-
-
Verhaak, R.G.1
-
13
-
-
40749101512
-
Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor
-
DOI 10.1158/1541-7786.MCR-07-0236
-
Reznik TE, et al. (2008) Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6:139-150. (Pubitemid 351378174)
-
(2008)
Molecular Cancer Research
, vol.6
, Issue.1
, pp. 139-150
-
-
Reznik, T.E.1
Sang, Y.2
Ma, Y.3
Abounader, R.4
Rosen, E.M.5
Xia, S.6
Laterra, J.7
-
14
-
-
34547881522
-
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
-
DOI 10.1073/pnas.0705158104
-
Huang PH, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867-12872. (Pubitemid 47255246)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.31
, pp. 12867-12872
-
-
Huang, P.H.1
Mukasa, A.2
Bonavia, R.3
Flynn, R.A.4
Brewer, Z.E.5
Cavenee, W.K.6
Furnari, F.B.7
White, F.M.8
-
15
-
-
67651174457
-
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts
-
Lal B, et al. (2009) EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8:1751-1760.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1751-1760
-
-
Lal, B.1
-
17
-
-
43749091506
-
Showering c-MET-dependent cancers with drugs
-
DOI 10.1016/j.gde.2008.02.001, PII S0959437X08000269
-
Knudsen BS, Vande Woude G (2008) Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 18:87-96. (Pubitemid 351694452)
-
(2008)
Current Opinion in Genetics and Development
, vol.18
, Issue.1
, pp. 87-96
-
-
Knudsen, B.S.1
Vande, W.G.2
-
18
-
-
77952555038
-
Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma
-
Van Meir EG, et al. (2010) Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin 60:166-193.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 166-193
-
-
Van Meir, E.G.1
-
19
-
-
61849083102
-
A highly invasive human glioblastoma pre-clinical model for testing therapeutics
-
Xie Q, et al. (2008) A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med 6:77.
-
(2008)
J Transl Med
, vol.6
, pp. 77
-
-
Xie, Q.1
-
20
-
-
19844368824
-
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion
-
DOI 10.1038/sj.onc.1208499
-
Xie Q, et al. (2005) Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24:3697-3707. (Pubitemid 40826869)
-
(2005)
Oncogene
, vol.24
, Issue.23
, pp. 3697-3707
-
-
Xie, Q.1
Gao, C.-F.2
Shinomiya, N.3
Sausville, E.4
Hay, R.5
Gustafson, M.6
Shen, Y.7
Wenkert, D.8
Vande, W.G.F.9
-
21
-
-
0034650543
-
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network
-
Webb CP, et al. (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349. (Pubitemid 30070761)
-
(2000)
Cancer Research
, vol.60
, Issue.2
, pp. 342-349
-
-
Webb, C.P.1
Hose, C.D.2
Koochekpour, S.3
Jeffers, M.4
Oskarsson, M.5
Sausville, E.6
Monks, A.7
Vande, W.G.F.8
-
22
-
-
35448962430
-
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
-
DOI 10.1158/0008-5472.CAN-07-0146
-
Zhang Q, et al. (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67: 10038-10046. (Pubitemid 47621255)
-
(2007)
Cancer Research
, vol.67
, Issue.20
, pp. 10038-10046
-
-
Zhang, Q.1
Yu, Y.A.2
Wang, E.3
Chen, N.4
Danner, R.L.5
Munson, P.J.6
Marincola, F.M.7
Szalay, A.A.8
-
23
-
-
77956296140
-
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth
-
Zhang YW, et al. (2010) MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 70:6880-6890.
-
(2010)
Cancer Res
, vol.70
, pp. 6880-6890
-
-
Zhang, Y.W.1
-
24
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
-
25
-
-
33144462553
-
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
-
Smolen GA, et al. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103:2316-2321.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 2316-2321
-
-
Smolen, G.A.1
-
26
-
-
34447272949
-
VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells
-
DOI 10.1016/j.bbrc.2007.06.094, PII S0006291X07012855
-
Oka N, et al. (2007) VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 360:553-559. (Pubitemid 47048135)
-
(2007)
Biochemical and Biophysical Research Communications
, vol.360
, Issue.3
, pp. 553-559
-
-
Oka, N.1
Soeda, A.2
Inagaki, A.3
Onodera, M.4
Maruyama, H.5
Hara, A.6
Kunisada, T.7
Mori, H.8
Iwama, T.9
-
27
-
-
33644820339
-
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
-
DOI 10.1016/j.ccr.2006.02.019, PII S1535610806000560
-
Phillips HS, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173. (Pubitemid 43357943)
-
(2006)
Cancer Cell
, vol.9
, Issue.3
, pp. 157-173
-
-
Phillips, H.S.1
Kharbanda, S.2
Chen, R.3
Forrest, W.F.4
Soriano, R.H.5
Wu, T.D.6
Misra, A.7
Nigro, J.M.8
Colman, H.9
Soroceanu, L.10
Williams, P.M.11
Modrusan, Z.12
Feuerstein, B.G.13
Aldape, K.14
-
28
-
-
33644769210
-
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts
-
DOI 10.1158/1078-0432.CCR-05-1793
-
Kim KJ, et al. (2006) Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12: 1292-1298. (Pubitemid 43342521)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.4
, pp. 1292-1298
-
-
Kim, K.J.1
Wang, L.2
Su, Y.-C.3
Gillespie, G.Y.4
Salhotra, A.5
Lal, B.6
Laterra, J.7
-
29
-
-
33750683969
-
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo
-
DOI 10.1158/1078-0432.CCR-05-1418
-
Martens T, et al. (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152. (Pubitemid 44703780)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.20 PART 1
, pp. 6144-6152
-
-
Martens, T.1
Schmidt, N.-O.2
Eckerich, C.3
Filibrandt, R.4
Merchant, M.5
Schwall, R.6
Westphal, M.7
Lamszus, K.8
-
30
-
-
73149091443
-
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
-
Buchanan SG, et al. (2009) SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 8:3181-3190.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 3181-3190
-
-
Buchanan, S.G.1
-
31
-
-
0035912757
-
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models
-
DOI 10.1073/pnas.131200498
-
Cao B, et al. (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98:7443-7448. (Pubitemid 32567968)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.13
, pp. 7443-7448
-
-
Cao, B.1
Su, Y.2
Oskarsson, M.3
Zhao, P.4
Kort, E.J.5
Fisher, R.J.6
Wang, L.-M.7
Vande, W.G.F.8
-
32
-
-
79955766450
-
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
-
Wen PY, et al. (2011) A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13:437-446.
-
(2011)
Neuro Oncol
, vol.13
, pp. 437-446
-
-
Wen, P.Y.1
-
33
-
-
77956680254
-
American Society of Clinical Oncology 2010: Report of selected studies from the CNS tumors section
-
Wen PY (2010) American Society of Clinical Oncology 2010: Report of selected studies from the CNS tumors section. Expert Review of Anticancer Therapy 10(9):1367-1369.
-
(2010)
Expert Review of Anticancer Therapy
, vol.10
, Issue.9
, pp. 1367-1369
-
-
Wen, P.Y.1
-
34
-
-
0037096867
-
Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma
-
DOI 10.1002/cncr.10594
-
Arrieta O, et al. (2002) Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer 94: 3210-3218. (Pubitemid 34670504)
-
(2002)
Cancer
, vol.94
, Issue.12
, pp. 3210-3218
-
-
Arrieta, O.1
Garcia, E.2
Guevara, P.3
Garcia-Navarrete, R.4
Ondarza, R.5
Rembao, D.6
Sotelo, J.7
-
35
-
-
77953287543
-
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value
-
Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J (2010) Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol 97:347-351.
-
(2010)
J Neurooncol
, vol.97
, pp. 347-351
-
-
Garcia-Navarrete, R.1
Garcia, E.2
Arrieta, O.3
Sotelo, J.4
-
36
-
-
19944430738
-
Enhanced growth of human MET-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor
-
Zhang YW, et al. (2005) Enhanced growth of human MET-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24:101-106.
-
(2005)
Oncogene
, vol.24
, pp. 101-106
-
-
Zhang, Y.W.1
|